Tuesday, July 17, 2018 4:46:08 PM
OMS-I140 -> slides 19-32 (first TNBC biomarker-only study, in which the investigator experimented with aPD-(L)1 after end of the official 28 day study https://clinicaltrials.gov/ct2/show/NCT02531425) It's really depressing to see how heavily these two patients had been treated before.
OMS-I141/Keynote 890 -> slides 33-35 (official combo study in which all accessible lesions will be treated, of course only shows study design, enrollment yet has to start https://clinicaltrials.gov/ct2/show/NCT03567720)
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM